Cynatas MSCs Effective in Model of Diabetic Wounds
Filed with ASX · · 3 pages · English
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- $5.2m placement of shares to Fidelity International
- Enrolment Completed in Cynatas Phase 1 Clinical Trial
- Notice of Allowance from EPO for Patent Application
- March 2018 Quarterly Report
- CYP Completes Patent Application related to CAR-T Therapy
Later from Cynata Therapeutics
- Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD
- Research Collaboration with UNSW for Coronary Artery Disease
- Positive 28-day Clinical Trial Data in Cohort B
- Product Development Program Update & Investor Presentation
- Cynata Enters Development Partnership with RCSI
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics